Xingxing Zang Laboratory


Image News


2021 Promising New Cancer Immunotherapy Drug. PDF

2021 Freeing Immune Cells to Combat Cancer. PDF

2020 A novel immune checkpoint inhibitor derived from our lab started clinical trials to treat cancer patients who have failed standard treatments or lack effective treatments.

2020 Patent (B7x and Its Derivatives for Treating and Preventing Cardiovascular Disease) was issued PDF

2019 A new pharmaceutical company was established based on our research

2019 MD-PhD student Peter John wins Lasker Essay Contest PDF

2019 Patent (TMIGD2 and Its Derivatives as Blockers or Binders of Cancer-expressed HHLA2 for Immunotherapies) was issued PDF

2019 MD/PhD Candidate Makes His Mark on Cancer Research and Bronx Kids' Program PDF

2018 Patent (HHLA2 as a Novel Inhibitor of Human Immune System and Uses Thereof) was issued PDF

2018 Scott Moerdler was offered Assistant Professor position at Rutgers University

2018 MD/PhD student Peter John received F30 Individual Predoctoral Fellowship Award from National Institutes of Health

2017 Our new immunotherapy technologies were licensed to a biopharmaceutical company in California

2017 A new pharmaceutical company was established based on our research

2017 The Zang lab and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. signed an agreement to develop new immunotherapy drugs

2016 Postdoctoral fellow Xudong Tang was offered faculty position

2016 Patent (Antibodies to Human B7x for Treatment of Cancer. Inventors: Xingxing Zang, James P. Allison) was issued PDF

2016 New immune checkpoint target emerges in bladder cancer PDF

2016 MD/PhD student Jordan Chinai received the first Barry R. Bloom Speaker Award

2016 The Zang lab and Jiangsu Hengrui Medicine Co., Ltd. signed an agreement to develop novel immunotherapy for human diseases PDF

2015 Wielding A Powerful Weapon PDF

2015 Amer Assal finished training and joined Memorial Sloan-Kettering Cancer Center

2015 Lustgarten-eBioscience Memorial Award PDF, American Association of Immunologists

2015 The Zang lab and Pfizer to jointly develop novel drugs for treating human cancers

2015 Congressionally Directed Medical Research Programs PDF

2014 MD/PhD student Kim Ohaegbulam received NRSA F31 Individual Predoctoral Fellowship Award from National Institutes of Health

2014 Hitting them with her best shot PDF

2014 Clinical fellow Murali Janakiram was offered Assistant Professor position in Montefiore Medical Center, Albert Einstein College of Medicine

2013 Our new cancer immunotherapy technology was licensed to a pharmaceutical company

2013 Oncology fellow Murali Janakiram was selected as a speaker at the Young Investigator Symposium in the ECOG-ACRIN Meeting [the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN)], Florida

2013 MD/PhD student Kim Ohaegbulam was invited as a Keynote Speaker for the Annual Moffitt Student Research Day at the Moffitt Cancer Center, Florida

2012 Postdoctoral fellow Kaya Ghosh was offered a job in industry

2012 PhD student Yael M Abadi successfully defended her PhD thesis

2012 PhD student Kimberly A Hofmeyer successfully defended her PhD thesis

2011 Albert Einstein Cancer Center PDF

2011 Postdoctoral fellow Jun Sik Lee was offered faculty position to start his own research lab

2009 DOD New Investigator Award PDF

2008 NIH Type 1 Diabetes Pathfinder Award PDF

2007 Cancer Research Institute PDF

2006 New Scientist magazine PDF

Xingxing Zang is solely responsible for the content of this site. Comments, concerns and questions regarding it should be addressed to him.

Click here to log in